GV 2207
Alternative Names: GV2207; HSV-2 vaccine - GenVecLatest Information Update: 29 Jun 2017
At a glance
- Originator GenVec
- Developer GenVec; National Institute of Allergy and Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 24 Feb 2017 GV 2207 is still available for partnering for further development (http://www.genvec.com) (GenVec's form 10-K, filed in March 2017)
- 28 Mar 2014 Discontinued - Preclinical for Herpes simplex virus infections (prevention) in USA (Parenteral)